Background Limited data exists on the long-term outcomes of patients with obscure gastrointestinal bleeding (OGIB) following single-balloon enteroscopy (SBE). Aim To examine the long-term outcomes of patients undergoing SBE for OGIB. Methods Consecutive patients undergoing SBE for OGIB at a tertiary care center between 2008 and 2010 were retrospectively identified. Clinical data and SBE findings were extracted from the medical record. Recurrence of OGIB during follow-up through 2012 was assessed by a combination of chart review and telephone interviews. Results One hundred and forty-seven patients were included in the study. The overall diagnostic yield of SBE was 64.6 % (95/147 patients). Findings of SBE included vascular lesions (VLs, 53.7 %), small bowel neoplasm (2.7 %), inflammatory lesions (4.8 %), and normal SBE (35.4 %). One hundred and ten patients (56.4 % female, mean age 70.6 ± 11.3 years) were followed for an average 23.9 months after initial SBE. During follow-up, OGIB recurred in 39.5 % of patients in whom a source of OGIB was identified on SBE and 55.9 % of patients with normal findings on SBE. OGIB recurred in 47.6 % of patients in whom small bowel VLs were treated endoscopically. None of the 13 patients in whom a non-VL lesion was identified as the source of bleeding on SBE experienced recurrent bleeding (p = 0.019).
Background
Obscure gastrointestinal bleeding (OGIB), defined as gastrointestinal blood loss for which no etiology can be identified on upper endoscopy, colonoscopy, and radiological evaluation, accounts for 5-10 % of gastrointestinal bleeding events, and in a majority of cases originates from the small bowel [1, 2] . The diagnosis and treatment of OGIB have been revolutionized in the past decade following the introduction of capsule endoscopy and doubleballoon enteroscopy (DBE) in 2001 [3, 4] . In patients with OGIB, DBE has a diagnostic yield of 60-70 %, and can deliver endoscopic therapy in the majority of cases where pathology is found [2, [5] [6] [7] [8] [9] [10] . Several studies have investigated the long-term outcomes of DBE-guided therapy for OGIB and found that the long-term remission rate of OGIB after DBE varies from 40 to 64 %. Gerson et al. found that bleeding resolved in 59 % of patients at 30 months, Shinozaki et al. reported 61 % of control of bleeding at 29.7 months, and, similarly, Samaha et al. reported the rebleeding rate of small bowel vascular lesions (VLs) was 46 % at 36 months [8, 11] . It is apparent from previous studies that successful control of OGIB following DBE-guided therapy depends on the underlying etiology; patients with small bowel VLs generally experience higher rates of rebleeding than those with other forms of small bowel pathology [5, 8, [11] [12] [13] [14] .
In 2008, the single-balloon enteroscopy (SBE) system was introduced as an alternative deep enteroscopy technique, with a balloon-tipped overtube sliding over an enteroscope [15] . When compared to DBE, some studies suggest that SBE is less effective in deeply intubating the small bowel and less likely to achieve total enteroscopy (TE) [16, 17] . On the other hand, a recent randomized multicenter trial demonstrated that SBE achieves comparable insertion depth, TE rate, diagnostic and therapeutic yield when compared to DBE [6] . Regardless of the modality utilized for evaluating the small bowel, in patients with OGIB the key question is whether the procedure results in long-term remission of bleeding, and not the insertion depth, TE rate, or diagnostic yield. While several groups have reported long-term outcomes of patients with OGIB treated with DBE, to date very limited data exists for SBE [18] . The purpose of our study, therefore, was to examine the long-term outcomes of patients undergoing SBE for the evaluation and treatment of OGIB.
Methods

Patients
Consecutive adult patients (C18 years old) who underwent SBE at the Barnes-Jewish Hospital/Washington University Medical Center in St. Louis for the evaluation of OGIB between March 2008 and July 2010 were identified from our institutional database for inclusion in the study. Patients were excluded if less than 3 months of follow-up after SBE examination was available, or if SBE was conducted for therapy of bleeding related to hereditary hemorrhagic telangiectasia. This study was approved by the Institutional Review Board of Washington University School of Medicine (# 201102055).
Obscure Gastrointestinal Bleeding
For the purpose of this study, OGIB was defined as gastrointestinal blood loss for which no etiology could be identified on upper endoscopy and colonoscopy [1] . Furthermore, OGIB was sub-classified as: (a) overt bleeding from the GI tract as reported by the treating physicians, or (b) occult bleeding, with a C2 g/dl drop in hemoglobin from recorded baseline values and positive fecal occult blood with no alternative explanation for anemia. A potential source of OGIB was defined as a lesion in the luminal GI tract with stigmata of recent bleeding (active bleeding, adherent clot, non-bleeding visible vessel, pigmented material at lesion base) in patients with overt bleeding, or luminal GI tract lesions (vascular malformation, ulcer, polyp, mass, etc.) known to cause blood loss in patients with occult bleeding.
SBE Procedure
All SBE procedures were performed by one of six experienced endoscopists (CHC, DE, SAE, SJ, DKM, FM), with propofol-based deep sedation administered by a nurse anesthetist under the supervision of an anesthesiologist. SBE procedures were performed using the Olympus SIF Q180 high-definition enteroscope and ST-SB1 balloontipped overtube (Olympus America, Center Valley, PA, USA). Insertion of the SBE system was accomplished using the ''hook-tip'' procedure described by Tsujikawa et al. [16] . Enteroscopy was initially performed via the oral route in all patients, unless prior endoscopic and radiologic studies indicated that the bleeding source was located in the distal small bowel. When route of examination was determined based on video capsule endoscopy (VCE) findings, the antegrade route was used when pathology was visualized during the initial 75 % of small bowel transit time and retrograde SBE was the initial route of examination in the remaining patients [19] . While the depth of insertion was not uniformly recorded, the most distal extent of examination was marked by tattooing with Spot (GI Supply, Camp Hill, PA, USA) in all cases. If the initial examination was non-diagnostic, patients were offered repeat SBE examination via the alternative route in cases where there was evidence of ongoing bleeding and/or a high index of suspicion for a potential source of blood loss in the unexamined portion of the small bowel based on prior studies (VCE or radiographic imaging). Preparation for the SBE procedure consisted of an overnight fast in all patients. Patients who underwent retrograde SBE received standard bowel preparation, consisting of 4 l of GoLytely on the night prior to the procedure.
Endoscopic therapy was applied when a potential bleeding source or active bleeding was encountered, and the method used was at the discretion of the endoscopists. All ulcers and mass lesions were biopsied and their locations marked by tattooing.
Data Collection
Demographics, results of prior endoscopic procedures, clinical parameters, comorbid medical illnesses and medication lists were recorded from electronic medical records. The overall burden of comorbid conditions was quantified using the Charlson comorbidity index (CCI) [20] .
Post-SBE Follow-Up Follow-up evaluation was performed at an average of 23.9 ± 10.3 months after the SBE, with follow-up data being collected through March 2012. Follow-up information was obtained from our institution's electronic medical records and/or telephone contact with the patients. A minimum of four attempts were made to contact each patient by telephone. At the time of telephone interview, patients who agreed to participate in the study were asked whether they had experienced any recurrent OGIB, defined as recurrent overt bleeding, hospitalization for GI bleeding, further interventions (endoscopic, radiologic, or surgical procedures), or need for blood transfusion or iron therapy. When applicable, cause of death was determined from the medical record.
Statistical Analysis
Data are reported as mean ± standard error for normally distributed data, and median and range for skewed data. Grouped continuous variable data were compared using two-tailed Student's t test and Mann-Whitney U test where appropriate. Intergroup and categorical comparisons were made using the Chi-square and Fisher's exact tests. A p value of \0.05 was required for statistical significance. All statistical analyses were performed using PASW 19.0 (SPSS, Inc., Chicago, IL, USA).
Results
Baseline Demographics
Between March 2008 and July 2010, 147 patients [69.6 ± 12.7 years old, 78 (53.1 %) female] underwent SBE for the evaluation of OGIB. Follow-up information was available for 110 patients whereas 37 patients were lost to follow-up (Table 1 ). There were no significant differences in baseline demographic characteristics between patients who were available for follow-up versus those who were lost to follow-up. Patients who were available for follow-up were more likely to have positive endoscopic findings (69.1 vs. 51.4 %, p = 0.011) and undergo SBEdirected therapy (69.1 vs. 35.1 %, p \ 0.001) than patients who were lost to follow-up.
SBE Findings and Interventions
A total of 150 SBE procedures were performed during the study period in 147 patients, including 146 SBE via the oral route (antegrade) and four via the anal route (retrograde). The average duration of the SBE procedure was 79.4 ± 22.9 min. Prior to SBE, patients had undergone a median of three (range 1-7) endoscopic procedures, and 103 (70.5 %) patients had undergone a video capsule endoscopy (VCE) either with the referring physicians or at our institution. Small bowel pathology was identified on VCE in 94 (91.3 %) cases, while the remaining nine patients had normal findings on VCE. The source of OGIB was identified by SBE in 95 of 147 (64.6 %) patients, and includes VLs (angioectasias and Dieulafoy's lesions) in 79 patients (53.7 %), small bowel mass in four (2.7 %) patients, and inflammatory lesions (ulcers or erosions) of the small bowel in seven patients (4.8 %) ( Table 1) . Previously missed foregut ulcerations were found in five (3.4 %) patients (three Cameron ulcers, two duodenal ulcers). SBE was normal to the depth of insertion in 52 patients (35.4 %). There was no significant difference in the diagnostic yield of SBE performed in patients with overt OGIB versus occult OGIB (62.5 and 67.1 %, respectively, p = 0.56). Endoscopic therapy was performed in 76 (51.7 %) patients and eight patients were referred to surgery. The only complication of SBE was a micro-perforation of the distal jejunum related to argon plasma coagulation of a VL, which was successfully managed conservatively.
Recurrent Bleeding in Long-Term Follow-Up
One hundred and ten patients were available for follow-up and 50 (45.1 %) of them experienced recurrent OGIB. Recurrent OGIB was not associated with any demographic characteristics, nadir hemoglobin level, comorbid conditions, antiplatelet or anticoagulation therapy, or initial presentation as overt or occult bleeding ( Table 2 ). The diagnostic yield of SBE did not differ significantly between procedures performed at an inpatient (20/31) versus outpatient setting (56/79; p = 0.5). There was a trend towards increased risks of recurrent bleeding in patients with valvular heart disease and in patients who had SBE performed as outpatients (p = 0.1 and p = 0.08, respectively). The pattern of recurrent bleeding changed in 19 of 50 (40.4 %) patients. In the 55 patients who initially presented with overt bleeding, 15 (26.8 %) patients experienced only occult blood loss during follow-up, while four of 55 (7.1 %) patients who initially presented with occult bleeding developed overt bleeding during follow-up. Although the pattern of bleeding changed in these patients, the diagnosis did not change during follow-up. Twenty (40 %) patients required blood transfusions while the remaining 30 were managed with oral or parenteral iron replacement therapy.
Twenty patients (18 %) died during the follow-up, at an average of 1.4 ± 0.7 years after SBE. One patient died secondary to abdominal sepsis following small bowel resection, one from sepsis in the setting of massive gastrointestinal bleeding, five from cardiovascular diseases, five from malignancies, two from end-stage liver disease, two from end-stage renal disease, and in four patients the causes of death were unknown.
SBE Findings and Recurrent GI Bleeding
The details of SBE findings in patients with follow-up are summarized in Table 3 . Recurrent OGIB occurred in 31 of 76 patients (40.8 %) in whom SBE revealed a source of OGIB, and in 19 of 34 patients (55.9 %) in whom SBE was normal (p = 0.11). Recurrent bleeding occurred in 47.6 % of patients who had VLs identified as the source of OGIB, which was not significantly different from the rebleeding rate of patients who had no pathologic findings on SBE (55.9 %, p = 0.47). On the other hand, if the identified cause of GI bleeding was not VLs, rebleeding occurred in 0 of 13 patients (p \ 0.001).
Therapeutic interventions based on SBE findings were performed in 76 patients. Endoscopic therapy directed at VLs was performed in 63 patients, of whom 31 (49.2 %) experienced recurrent bleeding. There was no significant difference in the rates of rebleeding between VLs that were actively bleeding during SBE (6/17, 35 %) versus VLs that were not bleeding during SBE (25/46, 54 %, p = 0.21).
Patients who received medical (proton pump inhibitors for peptic ulcers, chemotherapy for lymphoma, biologics for Crohn's disease, octreotide for radiation enteritis) or surgical therapy based on SBE findings were significantly During follow-up, 44 of 49 patients with persistent OGIB underwent 89 additional endoscopic and radiologic procedures, averaging 1.6 additional procedures (0-4) per patient. The remaining five patients with persistent occult gastrointestinal blood loss were managed conservatively with iron replacement therapy. Twenty-three patients underwent repeat SBE, with 15 of the procedures being performed for re-treatment of small bowel VLs. Eight patients with negative findings on initial SBE underwent a repeat examination, with negative findings in all cases. Additionally, three patients with recurrent overt bleeding underwent bidirectional DBE during follow-up. The findings of DBE were concordant with those of SBE: two patients with VLs, one without abnormality. OGIB persisted following DBE in all patients.
An etiology for OGIB was established during follow-up in five of 34 patients who had initial normal SBE. Colonoscopy revealed Crohn's disease of the terminal ileum in one patient who subsequently underwent a small bowel resection, and large internal hemorrhoids in another patient who underwent hemorrhoidectomy; in both cases OGIB resolved post-operatively. Angiography identified one small bowel VL, which was successfully treated with coil embolization. Capsule endoscopy detected an ulcerated small bowel carcinoid tumor, which was surgically resected. Computer tomography enterography (CTE) identified a chronically ischemic segment in the mid-ileum of a patient with sclerosing mesenteritis, which was surgically resected.
Discussion
In this retrospective cohort study, we reported the longterm outcomes of 110 patients following SBE performed for the evaluation of occult and overt OGIB. The diagnostic yield of SBE was 64.6 %, with vascular lesions being the predominant etiology of OGIB, and is in line with the previously reported diagnostic yield of SBE, which has ranged from 35 to 70 % [6, 21] . When the etiology of OGIB was identified on SBE, SBE-directed endoscopic, medical, and surgical therapy resulted in a long-term remission of OGIB in 59.2 % of patients.
During follow-up, OGIB recurred in 48 % of patients with vascular lesions, 56 % of patients with normal SBE, and 45 % for all patients. The overall rebleeding rate of our patients after SBE was 45 % with an average of 23.9 months of follow-up. This is similar to the 42 and 39 % rebleeding rate reported by Gerson and Shinozaki, respectively, in OGIB patients at 30 months follow-up after DBE (Table 4) . Furthermore, in Gerson's study the rebleeding rate decreased overtime, which may have been due to the definite treatment of lesions found or spontaneous cessation of bleeding. Therefore, it is possible that had we followed our patients longer, the rebleeding rate after SBE may be lower than 45 %.
The rebleeding rate of VLs in our study was 48 %, which is also similar to the reported rebleeding rate of VLs after DBE (Table 4) . Notably, the rate of recurrent bleeding in our patients with VLs was not significantly different from that in those who had an unremarkable evaluation of SBE (48.4 vs. 55.9 %, p = 0.47). The rebleeding rate of patients with normal DBE in Gerson's study was also similar to the rebleeding rate of VLs (45 vs. 42 %). This leads us to speculate that in the majority of patients without abnormalities found on deep enteroscopy, the cause of OGIB was due to small bowel VLs not detected by the deep enteroscopy. Indeed, significant small bowel pathology missed by the initial SBE was subsequently identified in only four (11.8 %) patients in our study, which is similar to the miss rate of 10.9 % based on the data from Gerson et al. [8] . Recently, Agrawal et al. [22] have observed that significant small bowel pathology was identified by CTE in 50 % of patients with overt OGIB and non-diagnostic capsule endoscopy. Indeed, one patient in our study had significant small bowel pathology discovered by CTE (ischemic small intestinal segment caused by sclerosing mesenteritis). In view of these results, we believe that CTE or MRE should be pursued in patients with persistent overt OGIB and negative endoscopic evaluations.
In a study of the long-term outcome of small bowel VL treated by DBE and argon plasma coagulation, May et al. [14] found that patients' overall transfusion requirement declined and the hemoglobin levels increased, yet the rebleeding rate was still 42 % at 55 months of follow-up. Similarly, we found that despite additional evaluation following SBE, close to half of our patients had persistent OGIB. Small bowel VLs are difficult to treat definitely for multiple reasons. VLs tend to occur in multiple locations and may not be easily detected during endoscopy. Additionally, VLs also tend to recur if the underlying medical conditions predisposing to VL recurrence are not corrected. Moreover, the 40-50 % long-term rebleeding rate of VLs in our and other deep enteroscopy studies mirrors the rebleeding rate of VLs in the placebo arms of randomized controlled trials of pharmacologic therapy for small bowel VLs [23, 24] . Considering the cost and the potential complications of repeated deep enteroscopies for the treatment of VLs, a comprehensive approach with the combination of endoscopic treatment and medical therapy may be needed to achieve a better and more cost-effective outcome.
In contrast to patients with small bowel VLs or normal SBE, no recurrent OGIB was observed in patients with inflammatory or neoplastic etiologies (p \ 0.001), also consistent with the findings seen in DBE [8, 11] . Therefore, balloon-assisted enteroscopy, whether DBE or SBE, is most effective in identifying small intestinal inflammatory and neoplastic pathologies and in directing subsequent medical and surgical therapy.
In this study, we attempted to identify risk factors for recurrent OGIB following SBE. However, we did not find an association between any patient's clinical or endoscopic factors and the risk of recurrent OGIB. In the subgroup of patients with VLs, we did not find a significant correlation between recurrence of gastrointestinal bleeding and the previously described risk factors for recurrent bleeding (valvular heart disease, number of observed lesions or use of anticoagulation) [5, 25] . This may be due to the fact that our study population had a high burden of systemic disease (median CCI 2.8), and thus the effect of these risk factors was overshadowed by the unmeasured confounders. It is also possible that our study was underpowered to detect the significant association. The major limitation of our study is its retrospective nature and limitations inherent to this study design. Loss of patient follow-up is another limitation. We attempted to minimize the impact of these factors by obtaining additional follow-up information through telephone interviews. We also found no significant difference between the patients with or without follow-up. Thirdly, SBE was performed mostly via the oral approach in our practice, and retrograde SBE was only pursued when a high index of suspicion for lesion in the distal small bowel was present based on prior capsule endoscopy or cross-sectional imaging. We do not believe that this significantly limits the generalizability of our results, as prior studies in patients undergoing bidirectional DBE have shown that most lesions responsible for OGIB are located in the proximal small bowel [8, 9, 26] . A final limitation is that due to the retrospective nature of the study, the insertion depth of SBE was not uniformly recorded and thus not reported in this study. Nevertheless, the main purpose of our study was to investigate the impacts of SBE on the clinical outcome of OGIB, not the insertion depth or TE rate. In addition, the fact that the diagnostic yield and the long-term outcome of SBE presented here are similar to the previously reported literature suggests that the insertion depth of SBE in this study is probably comparable to other studies, and does not affect our results.
In conclusion, SBE is a safe and effective procedure for evaluating and treating patients with OGIB. At an average of 23.9 months follow-up after SBE, 54.5 % of patients experienced no further bleeding. The rebleeding rate of patients treated by SBE in this study appears to be similar to the outcome observed in patients undergoing DBE for OGIB. Whereas there was no recurrent bleeding in patients who had inflammatory or neoplastic lesions identified on SBE, close to half of the patients who have small bowel VLs or normal SBE had recurrent OGIB. The optimal management of patients with small bowel VLs remains unclear.
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